Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

NCT06028074

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Georgiamune Inc
Enrollment	111 participants

Key Eligibility Criteria

Inclusion (10)

- General
- Written informed consent
- ECOG performance status 0-1.
- Laboratory assessment 28 days prior to enrollment for assessment of acceptable cardiac, renal and hepatic functions
- Recommended Double methods of contraception 90-days post treatment Cancer Specific

... and 5 more (see full listing online)

Exclusion (20)

- General
- Enrolled in any other interventional clinical trial, starting within 4 weeks of the first dose of GIM-122 and throughout the duration of the study, or is receiving other therapy directed at their malignancy
- Women who are pregnant or breastfeeding
- History of cardiac issues, pulmonary embolism, active and clinically significant bacterial, fungal, or viral infection d 6 months prior to dosing
- Contraindications to the imaging assessments or other study procedures that subjects will undergo or any medical or social condition that, in the opinion of the investigator, might place a subject at an increased risk, affect compliance, or confound safety or other clinical study data interpretation Cancer Specific

... and 15 more (see full listing online)

Locations (11 total)

The Angeles Clinic and Research Institute, Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
UCLA Hematology/Oncology, Los Angeles, California, United States
... and 8 more locations